BACKGROUND: Transfusion of ABO non-identical plasma, platelets and cryoprecipitate is routine practice even though adverse effects can occur. METHODS AND MATERIALS: Our hospital changed transfusion practice in 2005 and adopted a policy of providing ABO-identical blood components to all patients when feasible. We retrospectively compared the transfusion requirements, length of stay and in-hospital mortality in relation to ABO blood group in surgical patients who received platelet transfusions before and after this change to determine whether it resulted in any benefit. RESULTS: Prior to the change in practice, both group B and AB patients received more ABO non-identical platelet transfusion (P=0·0004), required significantly greater numbers of red cell transfusions (P=0·04) and had 50% longer hospital stays (P=0·039) than group O and A patients. Following the policy change, there was a trend for fewer red cell transfusions (P=0·17) and length of stay in group B and AB patients than group O or A patients. Overall, the mortality rate per red cell transfusion decreased from 15·2 per 1000 to 11·0 per 1000 (P=0·013). CONCLUSIONS: These results, in the context of previous findings, suggest that providing ABO-identical platelets and cryoprecipitate might be associated with reduction in transfusion requirements and improve outcomes in surgical patients.
BACKGROUND: Transfusion of ABO non-identical plasma, platelets and cryoprecipitate is routine practice even though adverse effects can occur. METHODS AND MATERIALS: Our hospital changed transfusion practice in 2005 and adopted a policy of providing ABO-identical blood components to all patients when feasible. We retrospectively compared the transfusion requirements, length of stay and in-hospital mortality in relation to ABO blood group in surgical patients who received platelet transfusions before and after this change to determine whether it resulted in any benefit. RESULTS: Prior to the change in practice, both group B and ABpatients received more ABO non-identical platelet transfusion (P=0·0004), required significantly greater numbers of red cell transfusions (P=0·04) and had 50% longer hospital stays (P=0·039) than group O and A patients. Following the policy change, there was a trend for fewer red cell transfusions (P=0·17) and length of stay in group B and ABpatients than group O or A patients. Overall, the mortality rate per red cell transfusion decreased from 15·2 per 1000 to 11·0 per 1000 (P=0·013). CONCLUSIONS: These results, in the context of previous findings, suggest that providing ABO-identical platelets and cryoprecipitate might be associated with reduction in transfusion requirements and improve outcomes in surgical patients.
Authors: Kenji Inaba; Bernardino C Branco; Peter Rhee; John B Holcomb; Lorne H Blackbourne; Ira Shulman; Janice Nelson; Demetrios Demetriades Journal: Arch Surg Date: 2010-09
Authors: A Shanwell; T M-L Andersson; K Rostgaard; G Edgren; H Hjalgrim; R Norda; M Melbye; O Nyrén; M Reilly Journal: Vox Sang Date: 2009-02-24 Impact factor: 2.144
Authors: Majed A Refaai; Jessie Carter; Kelly F Henrichs; Donna C Davidson; Stephen J Pollock; Ann E Casey; Sherry L Spinelli; Richard P Phipps; Charles W Francis; Neil Blumberg Journal: Transfusion Date: 2012-05-25 Impact factor: 3.157
Authors: Kelly F Henrichs; Nedda Howk; Debra S Masel; Mark Thayer; Majed A Refaai; Scott A Kirkley; Joanna M Heal; Neil Blumberg Journal: Transfusion Date: 2011-09-02 Impact factor: 3.157
Authors: Paul Vulliamy; Lucy Z Kornblith; Matthew E Kutcher; Mitchell J Cohen; Karim Brohi; Matthew D Neal Journal: Platelets Date: 2020-01-27 Impact factor: 3.862